Story
SK Biopharmaceuticals to Acquire Epilepsy Drug Portfolio from Biohaven for Up to $795 Million

SK Biopharmaceuticals has entered into a worldwide licensing agreement with Biohaven Bioscience Ireland to acquire rights to a portfolio of epilepsy treatments, including the drug candidate Opakalim. The deal, which could be worth up to $795 million, significantly expands SK Biopharmaceuticals' pipeline in the neurology sector.
Deal Structure and Financials
Under the terms of the agreement, SK Biopharmaceuticals will make an upfront payment of $400 million, according to a company filing on Wednesday. The initial payment is structured in two tranches:
- $350 million due upon the closing of the transaction.
- An additional $50 million to be paid one year after closing.
Beyond the upfront cash, the agreement includes potential milestone payments that bring the total value to $795 million. Biohaven is also set to receive tiered royalties based on future net sales of any commercialized products from the licensed assets.
Strategic Implications
AdThe acquisition provides SK Biopharmaceuticals with the rights to Opakalim and other compounds based on Kv7 activator technology. This deal also includes Biohaven's Kv7 discovery platform, giving the company broader capabilities for developing future treatments for epilepsy and other neurological disorders.
For Biohaven, the transaction monetizes a key part of its research and development pipeline, providing a substantial infusion of non-dilutive capital. The royalty structure ensures it will continue to benefit from the long-term commercial success of the assets it originally developed.
Market Reaction
Investors on both sides responded positively to the announcement. In stock market trading, shares of Biohaven (NYSE: BHVN) rose 5.12%, while SK Biopharmaceuticals (KRX: 326030) saw its shares climb 8.89%. The market reaction suggests that investors view the deal as strategically sound and financially beneficial for both companies, signaling confidence in the potential of the licensed drug platform.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.